A Single-center, Open-label, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxy Midazolam in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs ACT 132577 (Primary) ; Midazolam
- Indications Cardiovascular disorders; Hypertension
- Focus Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 28 Oct 2016 Status changed from recruiting to completed.
- 18 Aug 2016 Status changed from not yet recruiting to recruiting.
- 25 Jul 2016 New trial record